FDA Endorses New Pain Drug
This is a acetaminophen news story, published by CBS News, that relates primarily to Journavx news.
acetaminophen news
For more acetaminophen news, you can click here:
more acetaminophen newsJournavx news
For more Journavx news, you can click here:
more Journavx newsdrug discoveries news
For more drug discoveries news, you can click here:
more drug discoveries newsCBS News news
For more news from CBS News, you can click here:
more news from CBS NewsAbout the Otherweb
Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
Vertex Pharmaceuticals. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest opioid painkillers news, opioid medicines news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
pain drugCBS News
•Health
Health
FDA OK's painkiller designed to end opioids' addiction and overdose risk

77% Informative
Journavx is the first new pharmaceutical approach to treating pain in more than 20 years .
It's an alternative to both opioids and over-the-counter medications like ibuprofen and acetaminophen .
The medication's modest effectiveness and lengthy development process underscore the challenges of finding new ways to manage pain.
VR Score
86
Informative language
92
Neutral language
51
Article tone
semi-formal
Language
English
Language complexity
67
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
short-lived
External references
no external sources
Source diversity
no sources
Affiliate links
no affiliate links